Nautilus Biotechnology

Nautilus Biotechnology's Q3 2024 report shows increased net losses, R&D expenses, and G&A expenses, with plans to commercialize its proteomics platform by late 2025. The company faces challenges like supply chain disruptions and global events impacting operations.

Nautilus Biotechnology's Q3 2024 earnings call on Oct 29, 2024, featured Sujal Patel, Parag Mallick, and Anna Mowry discussing financial results. Forward-looking statements were made with caution due to risks and uncertainties.

Nautilus Biotechnology reported Q3 2024 financial results: operating expenses $19.1 million, net loss $16.4 million, cash, cash equivalents, and investments $221.2 million.

Operating expenses for Q3 2024 were $19.1 million, unchanged from the prior year. Personnel costs rose, offset by a one-time reduction in accrued incentive compensation. Sujal Patel, Nautilus CEO, expressed excitement about proteomics opportunities and the platform's impact on proteome exploration.

Nautilus Biotechnology reports Q3 2024 financial results: operating expenses $19.1M, net loss $16.4M, cash, cash equivalents, and investments $221.2M. CEO Sujal Patel highlights progress in proteomics and positive feedback from researchers.

Dimensional Fund Advisors LP increased its Nautilus Biotechnology, Inc. stake by 19.8% in Q2, owning 574,844 shares worth $1,345,000. Other investors also raised their stakes, with institutional investors and hedge funds owning 50.71% of the stock. VP Mary E. Godwin sold 47,031 shares at $2.87 each. Guggenheim initiated coverage with a 'buy' rating and a $6.00 price target. Nautilus Biotechnology's stock opened at $2.86 on Friday, with a market cap of $358.67 million.

Nautilus Biotechnology had a cash runway of about 2.8 years as of June 2024, with a cash burn of US$60m over the trailing twelve months. The company's cash burn rate increased by 24% in the last year, suggesting a shorter true cash runway if spending continues to rise. Nautilus Biotechnology could raise more cash without much trouble, though at the cost of some dilution.